Trials / Terminated
TerminatedNCT04438083
A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory Renal Cell Carcinoma (COBALT-RCC)
A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Allogeneic CRISPR-Cas9-Engineered T Cells (CTX130) in Subjects With Advanced, Relapsed or Refractory Renal Cell Carcinoma With Clear Cell Differentiation
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 19 (actual)
- Sponsor
- CRISPR Therapeutics AG · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a single-arm, open-label, multicenter, Phase 1 study evaluating the safety and efficacy of CTX130 in subjects with relapsed or refractory renal cell carcinoma.
Detailed description
The study may enroll approximately 107subjects in total.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CTX130 | CTX130 CD70-directed T-cell immunotherapy comprised of allogeneic T cells genetically modified ex vivo using CRISPR-Cas9 gene editing components. |
Timeline
- Start date
- 2020-06-16
- Primary completion
- 2024-10-08
- Completion
- 2024-10-08
- First posted
- 2020-06-18
- Last updated
- 2025-01-08
Locations
7 sites across 4 countries: United States, Australia, Canada, Netherlands
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04438083. Inclusion in this directory is not an endorsement.